MaxCyte (MXCT) Share Forecast & Price Target

Compare

10 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MXCT Analyst Ratings

Strong Buy

5 Buy

0 Hold

0 Sell

Based on 5 analysts giving stock ratings to

MaxCyte

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MXCT Stock 12 Month Forecast

Average Price Target

520.21p

▲(217.20%Upside)

Based on 5 Wall Street analysts offering 12 month price targets for MaxCyte in the last 3 months. The average price target is 520.21p with a high forecast of 668.85p and a low forecast of 371.58p. The average price target represents a 217.20% change from the last price of 164.00p.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"164":"164p","669":"669p","290.25":"290.3p","416.5":"416.5p","542.75":"542.8p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":668.84661,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">668.85p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":520.21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">520.21p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":371.58145,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">371.58p</span>\n  </div></div>","useHTML":true}}],"tickPositions":[164,290.25,416.5,542.75,669],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,165.5,204.21897,242.93794000000003,281.65691000000004,320.37588000000005,359.09485000000006,397.81382,436.53279000000003,475.25176000000005,513.97073,552.6897000000001,591.40867,630.12764,{"y":668.84661,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,165.5,192.78538461538463,220.07076923076923,247.35615384615386,274.64153846153846,301.9269230769231,329.2123076923077,356.4976923076923,383.7830769230769,411.0684615384616,438.3538461538462,465.6392307692308,492.92461538461544,{"y":520.21,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,165.5,181.35241923076924,197.20483846153846,213.0572576923077,228.90967692307692,244.76209615384616,260.6145153846154,276.4669346153846,292.31935384615383,308.1717730769231,324.0241923076923,339.8766115384616,355.7290307692308,{"y":371.58145,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":295,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":370,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":360,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":325,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":293,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":283,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":277,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":324,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":372,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":264,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":210,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":214,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":165.5,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target668.85p

Average Price Target520.21p

Lowest Price Target371.58p

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Matt HewittCraig-Hallum

Craig-Hallum

―

Buy

―

Reiterated

06/11/25

Craig-Hallum Keeps Their Buy Rating on MaxCyte (MXCT)

Matt LarewWilliam Blair

William Blair

―

Buy

―

Reiterated

05/08/25

MaxCyte's Strong Financial Performance and Growth Potential Justify Buy Rating

Daniel AriasStifel Nicolaus

Stifel Nicolaus

667.74p

Buy

307.16%

Upside

Reiterated

05/08/25

Stifel Nicolaus Sticks to Its Buy Rating for MaxCyte (MXCT)

Mark MassaroBTIG

BTIG

445.16p→370.97p

Buy

126.20%

Upside

Reiterated

05/08/25

MaxCyte's Strategic Growth and Stability: A Buy Rating by Analyst Mark Massaro

Brendan SmithTD Cowen

TD Cowen

―

Buy

―

Reiterated

05/07/25

MaxCyte's Strong Execution and Strategic Measures Earns Buy Rating Amid Market Challenges

Paul CuddonDeutsche Bank

Deutsche Bank

330p→500p

Buy

204.88%

Upside

Upgraded

10/10/24

MaxCyte upgraded to Buy from Hold at Deutsche BankMaxCyte upgraded to Buy from Hold at Deutsche Bank

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Matt HewittCraig-Hallum

Craig-Hallum

―

Buy

―

Reiterated

06/11/25

Craig-Hallum Keeps Their Buy Rating on MaxCyte (MXCT)

Matt LarewWilliam Blair

William Blair

―

Buy

―

Reiterated

05/08/25

MaxCyte's Strong Financial Performance and Growth Potential Justify Buy Rating

Daniel AriasStifel Nicolaus

Stifel Nicolaus

667.74p

Buy

307.16%

Upside

Reiterated

05/08/25

Stifel Nicolaus Sticks to Its Buy Rating for MaxCyte (MXCT)

Mark MassaroBTIG

BTIG

445.16p→370.97p

Buy

126.20%

Upside

Reiterated

05/08/25

MaxCyte's Strategic Growth and Stability: A Buy Rating by Analyst Mark Massaro

Brendan SmithTD Cowen

TD Cowen

―

Buy

―

Reiterated

05/07/25

MaxCyte's Strong Execution and Strategic Measures Earns Buy Rating Amid Market Challenges

Paul CuddonDeutsche Bank

Deutsche Bank

330p→500p

Buy

204.88%

Upside

Upgraded

10/10/24

MaxCyte upgraded to Buy from Hold at Deutsche BankMaxCyte upgraded to Buy from Hold at Deutsche Bank

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering MaxCyte

1 Month

xxx

Success Rate

8/21 ratings generated profit

Average Return

-1.53%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 38.10% of your transactions generating a profit, with an average return of -1.53% per trade.

3 Months

xxx

Success Rate

9/21 ratings generated profit

Average Return

-2.20%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 42.86% of your transactions generating a profit, with an average return of -2.20% per trade.

1 Year

Mark MassaroBTIG

Success Rate

5/21 ratings generated profit

Average Return

-17.70%

reiterated a buy rating 2 months ago

Copying Mark Massaro's trades and holding each position for 1 Year would result in 23.81% of your transactions generating a profit, with an average return of -17.70% per trade.

2 Years

xxx

Success Rate

0/21 ratings generated profit

Average Return

-39.40%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -39.40% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MXCT Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MXCT has received 7 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MXCT average Analyst price target in the past 3 months is 520.21.

Each month's total comprises the sum of three months' worth of ratings.

MXCT Financial Forecast

MXCT Earnings Forecast

Next quarter’s earnings estimate for MXCT is -0.08p with a range of -0.08p to -0.07p. The previous quarter’s EPS was -0.08p. MXCT beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.10% of the time in the same period. In the last calendar year MXCT has Outperformed its overall industry.

MXCT Sales Forecast

Next quarter’s sales forecast for MXCT is 7.30M with a range of 6.88M to 7.96M. The previous quarter’s sales results were 7.88M. MXCT beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year MXCT has Outperformed its overall industry.

MXCT Stock Forecast FAQ

What is GB:MXCT’s average 12-month price target, according to analysts?

Based on analyst ratings, MaxCyte Inc’s 12-month average price target is 520.21.

What is GB:MXCT’s upside potential, based on the analysts’ average price target?

MaxCyte Inc has 217.20% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MaxCyte Inc a Buy, Sell or Hold?

MaxCyte Inc has a consensus rating of Strong Buy, which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.

What is MaxCyte Inc’s share price target?

The average share price target for MaxCyte Inc is 520.21. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is 668.85p ,and the lowest forecast is 371.58p. The average share price target represents 217.20% Increase from the current price of 164p.

What do analysts say about MaxCyte Inc?

MaxCyte Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of MaxCyte Inc?

To buy shares of GB:MXCT, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

MaxCyte (MXCT) Share Forecast & Price Target

MXCT Analyst Ratings

MXCT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering MaxCyte

MXCT Analyst Recommendation Trends

MXCT Financial Forecast

MXCT Earnings Forecast

MXCT Sales Forecast

MXCT Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts